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Background: The highly genetically diverse HIV-1 group M subtypes may differ in their biological properties. Nef is
an important mediator of viral pathogenicity; however, to date, a comprehensive inter-subtype comparison of Nef
in vitro function has not been undertaken. Here, we investigate two of Nef’s most well-characterized activities, CD4
and HLA class I downregulation, for clones obtained from 360 chronic patients infected with HIV-1 subtypes
A, B, C or D.
Results: Single HIV-1 plasma RNA Nef clones were obtained from N=360 antiretroviral-naïve, chronically infected
patients from Africa and North America: 96 (subtype A), 93 (B), 85 (C), and 86 (D). Nef clones were expressed by
transfection in an immortalized CD4+ T-cell line. CD4 and HLA class I surface levels were assessed by flow
cytometry. Nef expression was verified by Western blot. Subset analyses and multivariable linear regression were
used to adjust for differences in age, sex and clinical parameters between cohorts. Consensus HIV-1 subtype B and
C Nef sequences were synthesized and functionally assessed. Exploratory sequence analyses were performed to
identify potential genotypic correlates of Nef function. Subtype B Nef clones displayed marginally greater CD4
downregulation activity (p = 0.03) and markedly greater HLA class I downregulation activity (p < 0.0001) than clones
from other subtypes. Subtype C Nefs displayed the lowest in vitro functionality. Inter-subtype differences in HLA
class I downregulation remained statistically significant after controlling for differences in age, sex, and clinical
parameters (p < 0.0001). The synthesized consensus subtype B Nef showed higher activities compared to consensus
C Nef, which was most pronounced in cells expressing lower protein levels. Nef clones exhibited substantial
inter-subtype diversity: cohort consensus residues differed at 25% of codons, while a similar proportion of codons
exhibited substantial inter-subtype differences in major variant frequency. These amino acids, along with others
identified in intra-subtype analyses, represent candidates for mediating inter-subtype differences in Nef function.
Conclusions: Results support a functional hierarchy of subtype B > A/D > C for Nef-mediated CD4 and HLA class I
downregulation. The mechanisms underlying these differences and their relevance to HIV-1 pathogenicity merit
further investigation.
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HIV-1 Nef is a 27-35 kDa myristoylated accessory protein
that promotes viral infectivity, replication and evasion of
host immune responses by manipulating several cellular
pathways [1-4]. The most well studied of Nef ’s diverse
functions include cell-surface downregulation of the HIV-1
receptor CD4 as well as HLA class I (HLA-I) molecules
that present viral epitopes to CD8+ T cells. Nef-mediated
CD4 downregulation enhances release of fully infectious
virions expressing HIV-1 envelope, thereby promoting viral
infectivity and replication [5-7]. Downregulation of HLA-A
and -B molecules promotes evasion of the host immune
response, while selective retention of HLA-C surface
expression allows infected cells to avoid recognition by
natural killer cells [8].
Nef plays an important role in HIV-1 pathogenesis.
Nef deletion dramatically impairs SIV pathogenicity in
rhesus macaques [9], and slow or non-progression to
symptomatic disease has been observed in humans
infected with rare Nef-deleted HIV-1 strains [10,11].
Furthermore, despite the general lack of gross mutational
defects in Nef among most HIV-1 elite controllers and
long-term non-progressors (LTNP) [12-14], one or more
Nef functions may be reduced in these individuals
[13,15,16], suggesting that more subtle variations in Nef
activity may modulate HIV-1 disease outcomes.
HIV-1 Nef sequences are highly diverse, with inter-
subtype nucleic acid variation ranging from 14.4% to
23.8% [17]. As such, Nef functions could vary among
viral subtypes. Indeed, differences in CD4 and HLA-I
downregulation activity have been demonstrated in single
patient-derived subtype B and D Nef clones [18], while
a patient-derived subtype C Nef demonstrated slightly
reduced ability to downregulate CD4 and HLA-I com-
pared to single subtype B, BF, and F Nef clones derived
from reference strains [19]. Defects in Nef-mediated
up-regulation of the HLA-II-associated invariant chain
(Ii) CD74 were also reported for the subtype C and F Nef
molecules in the same study [19]. Furthermore, a recent
study demonstrated HLA-I downregulation defects in
two subtype C and one group O Nef protein, and more
efficient CXCR4 downregulation in HIV-2 compared
to HIV-1 Nef proteins [20]. While these studies suggest
inter-subtype differences in Nef function, assessment
of single or few sequences may not be representative of
the subtype as a whole. Large-scale functional comparisons
of patient-derived Nef sequences from multiple HIV-1
subtypes are therefore required to address this issue.
HIV-1 subtypes may differ in their biological properties,
which can in turn impact their transmissibility or patho-
genic potential [21-23]. Understanding the basis of such
differences could be relevant to the development of
prevention or therapeutic strategies [22]. For example,
subtype C isolates appear to have lower replicationcapacity but equivalent, or increased, transmissibility com-
pared to those from other M group subtypes [21,22,24].
These somewhat paradoxical observations have been
hypothesized to at least partially explain the global pre-
dominance of subtype C [21]. Inter-subtype functional
comparisons have also demonstrated differences in the
activities of envelope gp120 [25], protease [26], reverse
transcriptase [27], vif [28], and long terminal repeat regions
[29], but to date no studies have comprehensively evaluated
Nef function in circulating HIV-1 sequences of different
subtypes.
Given the important role of Nef in HIV-1 pathogen-
esis, we investigated inter-subtype differences in two of
Nef ’s most well-characterized functions, CD4 and HLA-I
downregulation, using 360 plasma HIV-1 RNA-derived
subtype A, B, C and D Nef sequences derived from unique
untreated, chronically infected patients. Overall, we
observed a hierarchy of subtype B > A/D > C for both
Nef-mediated CD4 and HLA-I downregulation function.
Results
Selection and functional assessment of Nef clones
A single plasma HIV-1 nef sequence from each of 96
(subtype A), 93 (B), 85 (C), and 86 (D) individuals, whose
characteristics are summarized in Table 1, was cloned into
an expression plasmid featuring independent promoters
for nef and green fluorescent protein (GFP). Nef clones
clustered closely with their respective bulk plasma HIV
RNA sequences in a phylogenetic tree (not shown), were
free of gross genetic defects and were clearly classifiable as
subtype A, B, C or D by phylogenetic analysis (Figure 1).
Following transient transfection of each Nef expression
plasmid into a CEM-derived T cell line, Nef-mediated
downregulation of CD4 and HLA-A*02 was assessed by
flow cytometry and normalized to that of the control
subtype B strain Nef-SF2 (Figure 2). Concordance between
replicate measurements was excellent for CD4 and HLA-I
downregulation assays (Spearman’s, r = 0.97 and p < 0.0001
for both; not shown). Overall, the CD4 downregulation
function of patient-derived Nef clones ranged from 0%
to 104% relative to the activity of a positive control
Nef-SF2 (median [inter-quartile range; IQR] 99% [94-101])
(Figure 2A and B), while HLA-I downregulation function
ranged from 0% to 107% relative to Nef-SF2 (median [IQR]
86% [72-93]) (Figure 2C and D).
Verification of Nef protein expression by Western blot
Despite harboring an intact reading frame and no evidence
of gross sequence defects, 22 of 360 (6.1%) Nef clones (4%
subtype A, 2% subtype B, 16% subtype C and 2% subtype
D) displayed poor relative function (<35% that of control
Nef-SF2) for both CD4 and HLA-I downregulation
(Figure 2B and D). To test whether poor Nef function
could be attributable to impaired protein expression or
Table 1 Characteristics of study subjects infected with HIV-1 subtypes A, B, C and D
Subtype A Subtype B Subtype C Subtype D p-valueb
N = 96 N = 93 N = 85 N = 86
Sex (% female) 61 7.5 80 80 <0.0001
Age (years)a 35 (30–40) 37 (32–44) 31 (27–37) 33 (29–38) <0.0001
Plasma HIV-1 RNA (log10copies/ml)
a 4.95 (4.55–5.59) 5.28 (5.08–5.66) 4.65 (4.26–5.24) 4.88 (4.45–5.29) <0.0001
CD4 count (cells/mm3)a 154 (88–198) 200 (80–360) 369 (243–466) 128 (73–216) <0.0001
aMedians with inter-quartile ranges in brackets are shown.
bp-values calculated using the Kruskal-Wallis Test.
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poorly functional clones as well as a random selection of
60 clones with CD4 and HLA-I downregulation activities
above this threshold (Figure 2E). Of the 22 poorly func-
tional clones, 15 (68.2%) displayed weak or no detection of
Nef protein by Western blot (Figure 2B and D), whereas of
the 60 randomly selected functional clones, all but 3 were
readily detected. Furthermore, excluding the 15 poorly
functional and poorly expressed clones, no significant
differences in Western blot band intensity were observed
among HIV-1 subtypes (ANOVA, p = 0.83; not shown).
Although it is possible that the 15 poorly functional and
poorly detected clones represent Nef sequences that were
defective in vivo, we cannot rule out in vitro expression or
stability defects resulting from RT-PCR or cloning artifacts. A 
 C 
0.04
Figure 1 Maximum likelihood phylogenetic tree of patient-derived HI
and D (blue) Nef sequences form distinct clusters within the tree. The contThus, to be conservative, all 15 poorly functional clones
that could not be validated by Western blot were excluded
from subsequent analyses.
Inter-subtype comparison of Nef-mediated CD4 and HLA-I
downregulation
CD4 downregulation activities of HIV-1 subtype B Nef
clones were marginally yet significantly higher than the
other subtypes examined (median [IQR] subtype A, 98%
[94-101]; B, 100% [97-101]; C, 98% [90-101]; D, 99%
[96-101]) (Kruskal-Wallis, p = 0.03; Figure 3A). In con-
trast, Nef-mediated HLA-I downregulation activity differed
markedly among subtypes (median [IQR] subtype A,
84% [76-89]; B, 95% [90-99]; C, 79% [57-89]; D, 85%
[77-89]) (Kruskal-Wallis, p < 0.0001; Figure 3B). Subtype BSF2 
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Figure 2 Function and Nef expression of patient-derived HIV-1 Nef clones. Panel A: Representative flow cytometry plots depict expression
of surface CD4 (y-axis) and green fluorescent protein (GFP, x-axis), a marker of Nef-transfected cells, in control experiments. Cells transfected with
empty plasmid (Δ Nef, negative control) and cells transfected with wild-type Nef plasmid (SF2 Nef, positive control) are shown. Panel B: CD4
downregulation activities of subtype A (red), B (orange), C (green) and D (blue) Nef clones are shown. Open circles identify Nef clones that
displayed poor protein expression by Western blot. The solid black bar represents the median downregulation function, normalized to SF2 Nef.
Panel C: Representative flow cytometry plots depict expression of surface HLA-A*02 (y-axis) and GFP (x-axis) in control experiments, as described
in panel A. Panel D: HLA-I downregulation activities of subtype A (red), B (orange), C (green), and D (blue) Nef clones are shown. Open circles
identify Nef clones that displayed poor expression by Western blot. The solid black bar represents the median downregulation function,
normalized to SF2 Nef. Panel E: Detection of Nef clones by Western blot using rabbit anti-Nef serum. Cells transfected with control SF2 Nef, ΔNef,
and two representative patient-derived Nef clones from each subtype are shown.
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downregulation capacities compared to those of all
other subtypes tested (Dunn’s multiple comparisons test,
all p < 0.001; Figure 3B). We observed a modest as-
sociation between Nef-mediated CD4 and HLA-I
downregulation activities for patient-derived Nef clonesA B C D
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Figure 3 Inter-subtype comparison of Nef-mediated CD4 and HLA-I down
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that HLA-B molecules are downregulated less efficiently
than HLA-A molecules [31]. Therefore, we also assessed
the ability of Nef to downregulate HLA-B molecules
for a subset of 24 clones spanning all subtypes, using a
CEM T-cell line stably expressing HLA-B*07. The correl-
ation between Nef ’s ability to downregulate A*02 and
B*07 was robust (Spearman’s, r = 0.89 and p < 0.0001;
Figure 4), indicating that HLA-A*02 downregulation
measurements are generally representative of Nef ’s ability
to downregulate both HLA-A and -B.
Addressing demographic and clinical characteristics as
potential confounders
Nef function might differ according to HIV-1 disease
stage [32,33] and clinical status [13,15,16]. Furthermore,
substantial demographic differences are observed in
HIV-infected populations globally (Table 1). Although
no significant correlations were observed between Nef func-
tion and patient viral load or CD4 count in any individual
subtype (all p > 0.05; not shown), we nevertheless wanted to
control for differences in age, sex, and clinical parameters
among cohorts. We did so using two approaches. First, we
restricted our analysis to a subset of patients who were
matched for viral load and CD4 cell counts. Second, we
conducted a multivariable analysis adjusting for patient
demographic and clinical characteristics directly.
Firstly, we identified 30 patients per subtype with com-
parable plasma viral loads (median [IQR] 5.11 log10 copies/0 25 50 75 100
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Figure 4 Comparison of Nef-mediated HLA-A*02 and HLA-B*07
downregulation capacities. A strong positive correlation
(Spearman’s, r = 0.89 and p < 0.0001) between Nef-mediated HLA-A
*02 and HLA-B*07 downregulation capacities of 24 patient-derived
Nef clones of subtypes A (red), B (orange), C (green) and D (blue)
is shown.ml [4.73-5.50], p = 0.92) and CD4 counts (overall median
[IQR] 199 cells/mm3 [89-286], p = 0.7). Despite reduced
statistical power, Nef function in this clinically-matched
subset was consistent with our original observations
(Kruskal-Wallis, p = 0.03 and p < 0.0001 for inter-subtype
differences in CD4 and HLA-I downregulation activities,
respectively; Figure 5). Furthermore, the relative hierarchy
of Nef function and the magnitude of inter-subtype differ-
ences also remained consistent: subtype B Nef clones from
clinically-matched participants exhibited modest yet sig-
nificantly higher CD4 downregulation activities than those
from subtype C (median [IQR] subtype A, 98% [92-100];
B, 100% [98-102]; C, 96% [89-100]; D, 99% [97-100])
(Dunn’s multiple comparisons tests, p < 0.05; Figure 5A).
Subtype B Nef clones also displayed significantly higher
HLA-I downregulation activities than those from subtypes
A, C and D (median [IQR] subtype A, 84% [77-89]; B,
97% [88-99]; C, 80% [60-87]; D, 86% [79-91]) (Dunn’s
multiple comparisons tests, p < 0.05; Figure 5B).
Secondly, using the entire dataset, we performed univar-
iate and multivariable linear regression to investigate the
relationship between Nef function and HIV-1 subtype,
log10 plasma viral load, logCD4 count, sex and age
(Table 2). In the multivariable analyses, log10 plasma
viral load remained significantly associated with Nef-
mediated CD4 downregulation (with a 3.3% increase in
CD4 downregulation activity per log10 plasma viral load
increase, p = 0.02), while a trend remained for subtype A
and C Nef clones having on average 4.8% (p = 0.06) and
5.0% (p = 0.07) lower CD4 downregulation activity, respect-
ively, than those from subtype B after adjusting for log10
plasma viral load (Table 2). In the multivariable analysis
of Nef-mediated HLA-I downregulation, HIV-1 subtype
emerged as the single significant predictor of function,
with subtypes A, C and D Nef clones exhibiting adjusted
averages of 16%, 24% and 16% lower function, respectively,
compared to those from subtype B (p < 0.0001) (Table 2).
Inter-subtype differences in Nef function observed using
subtype consensus sequences
To further investigate inherent differences in Nef function
among HIV-1 group M subtypes, we synthesized, cloned
and assessed in vitro CD4 and HLA-I downregulation activ-
ities of the consensus Nef sequences for subtype B (which
was anticipated to display highest function) and subtype C
(which was anticipated to display the lowest function)
(2004 consenses, available at http://www.hiv.lanl.gov/con-
tent/sequence/NEWALIGN/align.html). Differences in Nef
function were noted between subtype consenses, which
was most apparent for HLA-I downregulation and
appeared to be dependent on Nef protein expression levels
(Figure 6A, 6B). Whereas consensus B Nef efficiently
downregulated HLA-I at low protein concentrations
(Figure 6A), greater doses of consensus C Nef were
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Figure 5 Inter-subtype comparison of Nef-mediated CD4 and HLA-I downregulation capacities in a subset of individuals matched for
plasma viral load and CD4 count. Panels A and B: CD4 (A) and HLA-A*02 (B) downregulation activities of subtype A (red), B (orange), C (green)
and D (blue) patient-derived Nef clones from selected individuals matched for patient plasma viral loads and CD4 counts are shown (n = 30 per
subtype). Bars and whiskers represent the median and inter-quartile ranges, respectively. Kruskal-Wallis with Dunn’s post-hoc tests were used to
compare Nef functions between subtypes. The Kruskal-Wallis p-value is shown and significant differences between individual subtypes are
indicated by asterisks; p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***).
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(Figure 6B). Indeed, when HLA-I downregulation data
were analyzed according to tertiles of protein expression,
consensus C Nef displayed 21.2% lower activity than
consensus B Nef in cells expressing low amounts of
protein, 4.0% lower activity in cells expressing moderate
levels of protein, and equivalent (0.6% lower) activity
in cells expressing the highest amounts of Nef protein,
yielding an overall difference of 3.6% (Figure 6C). A
similar, although less marked dose-dependent relationship
was observed for Nef-mediated CD4 downregulation, with
consensus C Nef displaying 6.1% lower activity than con-
sensus B Nef in cells expressing low amounts of protein,
and 1.5% lower activity overall (not shown).Table 2 Linear regression models investigating the relationsh
characteristics, clinical parameters and HIV-1 subtype
Variable Univariate (CD4) Multivariable (CD4
Estimate p-value Estimate p-
Subtype A −0.060 0.02 −0.048 0.0
B 0 N/A 0 N/
C −0.072 0.007 −0.051 0.0
D −0.028 0.3 −0.012 0.7
Log viral load 0.040 0.002 0.033 0.0
Log CD4 −0.009 0.7 - -
Male 0.026 0.2 - -
Age −0.0006 0.6 - -
β Estimates for log viral load and log CD4 count are expressed per log10 increment
For HIV-1 subtype, B is the reference group.
aMultivariable model for CD4 downregulation: multiple r2 = 0.045, p = 0.006.
bMultivariable model for HLA-I downregulation: multiple r2 = 0.14, p < 0.0001.Genotypic correlates of differential Nef function
As expected [17,34], Nef clones exhibited substantial
inter- and intra-subtype diversity (HXB2-aligned clonal
Nef amino acid sequences provided in Additional file 1:
Table S1). Cohort consensus Nef amino acid sequences
for subtypes A-D differed at 52 of 206 codons (25%)
(Figure 7A), of which 10 differences were positioned at
residues or within motifs reported to be involved in
modulating CD4 or HLA-I downregulation [1,2,20,35-43]
(Figure 7A and 7B). A comparison of amino acid frequen-
cies between subtype B and C sequences identified 32 resi-
dues (15.5%) that differed in their consensus amino acid,
and a further 29 residues (14.1%) that differed by at least
15% in their major amino acid frequency (Figure 7C). It isip between Nef function and socio-demographic
)a Univariate (HLA-I) Multivariable (HLA-I)b
value Estimate p-value Estimate p-value
6 −0.14 <0.0001 −0.16 <0.0001
A 0 N/A 0 N/A
7 −0.21 <0.0001 −0.24 <0.0001
−0.13 <0.0001 −0.16 <0.0001
2 0.050 0.003 - -
−0.013 0.6 - -
0.057 0.02 −0.06 0.06
0.000001 0.94 - -
. Age is expressed per year increment. For sex, female is the reference group.
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Figure 6 Analysis of Nef HLA-I downregulation capacity for LANL 2004 consensus B and C Nef sequences. Consensus B and C Nef
sequences were obtained from the Los Alamos National Laboratory HIV Sequence database (2004 update), synthesized and tested. Panels A and
B: Representative flow cytometry plots depict expression of surface HLA-A*02 (y-axis) and green fluorescent protein (GFP, x-axis), a marker of
Nef-transfected cells. Representative flow cytometry plots for cells transfected with consensus B Nef plasmid (A) or consensus C Nef plasmid
(B) are shown. HLA-I downregulation activity was assessed in tertiles of cells expressing low, medium (med), or high amounts of Nef, as indicated
by the level of GFP co-expressed by the dual promoter plasmid. Panel C: Results from ten replicate assays are shown, indicating a reduced ability
of consensus C Nef to downregulate HLA-I, particularly in cells expressing the lowest amount of Nef protein. For comparison, the outcome when
all cells are gated together is also presented. Bars and whiskers represent the mean and standard error of the mean for each group, respectively.
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functional differences include amino acids at one or more
of these sites.
Next, we examined genotypic determinants of Nef
function within subtypes and then assessed whether these
could also shed light on observed functional differences
between subtypes. Firstly, Nef amino acid length (median
206, 207, 207, 208 residues in subtypes A, B, C and D,
respectively) did not correlate with CD4 or HLA-I
downregulation activity for any of the subtypes (Spearman’s,
r ≤ 0.17 and p ≥ 0.1; not shown). Secondly, intra-subtype
analyses identified 33 amino acids occurring at 22 unique
Nef codons that were associated with differential HLA-I
downregulation activity in at least one subtype (p < 0.05
and q ≤ 0.4; Table 3). However, using this approach, noNef residues were identified as being associated (at q < 0.4)
with CD4 downregulation function in any subtype. Thirdly,
as we were particularly interested in sequence correlates for
the least functional Nef clones, we compared amino acid
frequencies in subtype C Nef sequences from the highest
vs. lowest functional quartiles for CD4 downregulation.
Of interest, the lowest-function subtype C Nef clones
were enriched for non-consensus 88G while the highest-
function clones were 100% conserved for consensus 88S
(Bonferroni-corrected p = 0.02). No additional amino acids
were identified following Bonferroni correction in a
similar analysis undertaken for HLA-I downregulation;
however, we noted that subtype C Nef clones with the
lowest HLA-I downregulation function displayed higher
sequence conservation at Nef codons 8-12 (Student’s T
N N
CC
M20
EEEE62-65
VGF66-68
LL164-165
DD174-155
R105
A
B C
8-14
88
Figure 7 Inter-subtype comparison of Nef sequences in the context of known Nef functional motifs. Panel A: Consensus A, B, C
and D Nef sequences were determined using patient-derived clones from this study and are shown aligned to HXB2. Amino acid
residues/motifs previously associated with Nef-mediated modulation of CD4 downregulation (magenta), HLA-I downregulation (cyan) or
both (purple) are indicated. Insertions were observed at codons 23, 24, 25, 63, 64, and 65 in greater than 10% of clones for at least one
subtype (indicated by asterisks). Panel B: The position of residues/motifs associated with Nef CD4 downregulation (magenta), HLA-I
downregulation (cyan), or both functions (purple) are highlighted on a structure model of the Nef protein (composite crystal structure
kindly provided by Art F. Y. Poon, [44]). Panel C: The position of amino acids whose sequence varied between consensus B and C Nef
sequences from this study are shown using a structure model of Nef. Differences between consensus sequences (32 residues) are
highlighted in red and majority amino acids whose frequency varied by greater than 15% between B and C (additional 29 residues) are
indicated in orange.
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associated with intra-subtype differences in function also
varied in frequency among subtypes [45] (Table 4). Of the
36 Nef residues associated with intra-subtype function,
33 also displayed significantly different inter-subtype
frequencies. Of interest, amino acid frequencies in theregion spanning codons 8-14 and at codon 88 (all p < 0.05
and q < 0.05; Table 4 and Figure 7C) were coincident with
functional differences observed between subtypes.
Given the extensive inter- and intra-subtype sequence
differences observed in Nef, and the expectation that
complex codon co-varation pathways are possible [46],
Table 3 Amino acids associated with intra-subtype Nef HLA-I downregulation function
Subtype Codona AAb Cons.c Functiond No. of samplese p-value q-value
+ AA - AA + AA -AA
A 3 G G 82.3 87.1 71 23 0.007 0.4
9 R S 94.5 83.1 5 84 0.02 0.4
11 V V 81.5 87.9 74 16 0.007 0.4
83 G G 80.6 87.0 63 31 0.01 0.4
89 F H 90.8 82.4 15 79 0.01 0.4
105 R K 78.4 85.0 22 72 0.02 0.4
120 Y Y 82.4 86.7 56 38 0.02 0.4
168 M I 87.1 81.9 23 71 0.02 0.4
191 L L 81.0 87.1 57 37 0.005 0.4
196 Q R 80.2 86.2 34 60 0.008 0.4
B 8 R S 98.2 94.6 28 56 0.006 0.2
8 S S 94.3 98.0 38 46 0.0009 0.2
14 P P 94.4 97.7 58 34 0.01 0.2
28 A D 101.5 95.0 7 85 0.004 0.2
65 D E 89.7 96.4 8 84 0.02 0.3
65 E E 96.4 87.3 83 9 0.009 0.2
89 F H 63.7 95.6 5 87 0.03 0.4
89 H H 95.7 60.8 86 6 0.007 0.2
98 D E 99.7 95.1 6 86 0.02 0.3
98 E E 95.0 100.6 85 7 0.007 0.2
105 Q K 91.0 96.5 18 74 0.03 0.4
153 I V 90.5 96.7 16 75 0.007 0.2
153 V V 96.7 90.0 74 17 0.003 0.2
198 K L 98.8 94.7 19 73 0.01 0.2
202 F Y 99.4 95.0 9 83 0.01 0.2
202 Y Y 95.0 99.4 83 9 0.01 0.2
C 9 S S 78.1 96.6 66 5 0.01 0.3
40 H H 84.0 72.3 38 36 0.005 0.3
40 Y H 72.3 84.0 34 40 0.003 0.3
102 H Y 56.2 81.8 12 62 0.02 0.4
105 K K 83.5 71.1 53 21 0.005 0.3
105 R K 57.8 82.5 15 59 0.01 0.3
108 D E 71.1 83.7 37 37 0.01 0.3
108 E E 83.7 71.1 37 37 0.01 0.3
182 Q K 49.6 80.7 8 66 0.01 0.3
aNumbered according to HXB2.
b Amino acid variants associated with differences in HLA-I downregulation function. Only common amino acid variants (present at n ≥ 5 in each subtype)
were investigated.
cConsensus amino acid for the codon and subtype indicated.
dMedian HLA-I downregulation function (expressed as a percentage relative to SF2) of Nef sequences with (+AA) and without (-AA) the amino acid variant.
eNumber of sequences with (+AA) and without (-AA) the amino acid variant. Amino acid totals vary, as gaps in the alignment are considered missing data.
A similar intra-subtype analysis was performed to identify Nef amino acids associated with CD4 downregulation function; no associations q < 0.4 were identified
using this approach.
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function will require substantial further study. Towards
this end, we constructed S9R and S88G mutants inconsensus B and C backbones, and assessed their abil-
ity to downregulate HLA-I and CD4, respectively. As
expected, introduction of non-consensus 9R increased
Table 4 Frequencies of amino acids associated with altered intra-subtype Nef function
Function Codona AA Subtypeb +/-c % Frequency p-value q-value
A B C D
CD4 88 G C - 10 2 20 2 <0.0001 <0.0001
88 S C + 90 97 80 98 0.0001 0.0001
HLA-I 3 G A - 76 95 66 81 <0.0001 <0.0001
8-12 SSIVG C - 82 48d 81 88 <0.0001 <0.0001
8 R B + 10 30 7 12 <0.0001 <0.0001
8 S B - 80 41 81 81 <0.0001 <0.0001
9 R A + 5 9 4 0 0.05 0.06
9 S C - 87 70 89 88 0.0008 0.001
11 V A - 79 34 74 88 <0.0001 <0.0001
14 P B - 89 63 93 94 <0.0001 <0.0001
28 A B + 14 8 1 4 0.007 0.008
40 H C + 86 79 51 93 <0.0001 <0.0001
40 Y C - 10 14 46 5 <0.0001 <0.0001
65 D B - 11 9 1 8 0.13 0.13
65 E B + 86 90 97 87 0.08 0.09
83 G A - 67 57 45 31 <0.0001 <0.0001
89 F A/B +/- 16 5 97 5 <0.0001 <0.0001
89 H B + 82 93 0 95 <0.0001 <0.0001
98 D B + 85 7 47 31 <0.0001 <0.0001
98 E B - 15 92 53 69 <0.0001 <0.0001
102 H C - 9 25 16 1 <0.0001 <0.0001
105 K C + 73 54 72 78 0.004 0.005
105 Q B - 2 20 8 13 0.001 0.002
105 R A/C -/- 23 26 20 9 0.03 0.04
108 D C - 15 86 50 45 <0.0001 <0.0001
108 E C + 84 13 50 55 <0.0001 <0.0001
120 Y A - 60 93 35 62 <0.0001 <0.0001
153 I B - 1 17 1 9 <0.0001 <0.0001
153 V B + 99 80 99 87 <0.0001 <0.0001
168 M A + 24 61 76 39 <0.0001 <0.0001
182 Q C - 5 28 11 1 <0.0001 <0.0001
191 L A - 61 3 0 1 <0.0001 <0.0001
196 Q A - 36 0 0 0 <0.0001 <0.0001
198 K B + 10 21 35 33 0.0002 0.0002
202 F B + 62 10 23 62 <0.0001 <0.0001
202 Y B - 35 90 69 38 <0.0001 <0.0001
aNumbered according to HXB2.
bIndicates the subtype in which the amino acid is associated with altered Nef function.
cIndicates whether the amino acid is associated with increased (+) or decreased (-) Nef function.
dThe consensus for subtype B is SSVVG and is 52% conserved.
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bones, while introduction of non-consensus 88G reduced
CD4 downregulation in both B and C backbones; however,
the magnitudes of these effects were modest (≤3%) in all
cases (data not shown).Discussion
This study investigated differences in two of HIV-1 Nef ’s
most well-characterized functions, CD4 and HLA-I down-
regulation, using unique plasma RNA-derived Nef clones
obtained from 360 untreated individuals chronically
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subtype differences in Nef-mediated CD4 downregulation
activity were relatively modest, those for HLA-I down-
regulation were substantial. For both activities, a hierarchy
of Nef function was observed, with subtype B > A/D >C.
These differences remained statistically significant in
analyses of a subset of Nef clones from subjects who
displayed similar clinical values for plasma viral load and
CD4 cell count. In addition, HIV-1 subtype remained
the sole significant correlate of Nef-mediated HLA-I
downregulation function in multivariable analyses that
controlled for differences in age, sex, and clinical char-
acteristics. After controlling for these other factors, we
estimate that naturally occurring HIV-1 Nef sequences
differ in their ability to downregulate CD4, on average, by
up to 5% between subtypes, whereas downregulation of
HLA-I differs, on average, by up to 24% between subtypes
(Table 2). In addition, a comparison of consensus subtype
B and C Nef sequences confirmed greater in vitro function
for subtype B Nef, which was most pronounced at low
Nef protein concentrations. Further supporting these
observations, in an independent study of 73 patient-
derived clonal Nef sequences from a different cohort of sub-
type C-infected South African patients, we observed ~5%
and ~24% lower median CD4 and HLA-I downregulation
activities, respectively, compared to the subtype B control
SF2 Nef [47]. Taken together, our results support signifi-
cant inherent differences in Nef-mediated HLA-I down-
regulation function, and possibly modest differences in
CD4 downregulation, between HIV-1 subtypes.
Nef-mediated CD4 downregulation promotes HIV-1
infectivity by increasing virion incorporation of envelope
[5-7], and this activity correlates with Nef ’s ability to en-
hance viral replication capacity [48]. It is tempting to specu-
late that the modest reduction in CD4 downregulation
activity observed for subtype C Nef clones could result in
a lower replication capacity for HIV-1 subtype C strains
compared to other M group subtypes [21] – perhaps in
conjunction with functional differences in envelope gp120
[25] and reverse transcriptase [27], but not other viral
regions [27-29]. Indeed, it has been proposed that lower
replication capacity but equal (or perhaps enhanced)
transmissibility of subtype C isolates favor their ability
to spread, and thus contribute to their higher global
prevalence [21,24,49]. Although inter-subtype differences
in HIV-1 pathogenicity or rate of disease progression
remain controversial [21-23,50-54], it is conceivable that
the diversity in Nef functions observed in this study could
contribute to inherent differences in the intra- and inter-
subtype pathogenicity of globally diverse HIV-1 strains.
Consistent with a recent comparison of HIV-1 group
M, group O and HIV-2 Nef sequences [20], intra- and
inter-subtype dynamic ranges of HIV-1 Nef-mediated
HLA-I downregulation activity were broader than thosefor CD4 downregulation, suggesting that preservation of
Nef ’s ability to modulate CD4 may be more essential
in vivo. Indeed, disruption of Nef motifs involved in
CD4 downregulation and enhancement of viral infectivity
revealed that these Nef functions were critical for viral
replication in early SIV infection, and thus that HLA-I
downregulation alone was not adequate for SIV virulence
[55]. In addition, although Nef sequences with efficient
HLA-I downregulation activity were selected during early
SIV and HIV infection [33,56], elimination of this function
did not significantly impact SIV viral loads [56]. Further-
more, while Nef-mediated CD4 downregulation is typically
maintained or enhanced throughout the HIV-1 disease
course [33], Nef ’s HLA-I downregulation activity appears
to be maintained in chronic infection [48], but is reported
to diminish after progression to AIDS [33]. Further studies
will be required to fully assess the relative contribution of
various Nef functions to HIV-1 pathogenesis [1].
Substantial inter-subtype sequence diversity was observed
among Nef clones. For example, between subtypes B and
C, nearly one-third of Nef codons differed by at least 15%
in their major amino acid frequencies. Similarly, of the 45
residues previously reported to play a role in CD4 and
HLA-I downregulation, 16 (35.5%) differed by at least 15%
in their major amino acid frequencies between at least two
subtypes (Figure 7 and Additional file 1: Table S1), yielding
potential candidate domains to examine in future studies
aimed at elucidating the mechanisms underlying observed
inter-subtype functional differences.
While major determinants of Nef-mediated CD4 and
HLA-I downregulation functions appear to be genetically
separable [1,33,55], our observation of a modest positive
correlation between these activities in patient-derived
sequences (Figure 3C) suggests that secondary or
shared genetic determinants may also affect these protein
activities. To this end, we also undertook exploratory ana-
lyses to identify residues associated with intra-subtype dif-
ferences in Nef function. Several Nef residues identified in
this way also differed in frequency between subtypes,
highlighting potential additional mediators of observed
inter-subtype functional differences. In agreement with
our previous study of Nef function in HIV-1 subtype
B-infected elite controllers [16], global consensus amino
acids 8S, 11 V, and 14P in the N-terminal domain (adjacent
to Nef ’s myristoylation motif [2]) were associated with
lower HLA-I downregulation in intra-subtype analyses.
These consensus residues, together with consensus 9S (also
associated with decreased HLA-I downregulation in the
present study, and subsequently validated by site-directed
mutagenesis), were considerably less frequent in subtype B
Nef clones compared to those from subtypes A, C and D,
consistent with the superior HLA-I downregulation activity
of subtype B. Moreover, subtype B Nef clones were overall
significantly less well conserved at residues 8-12, and
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downregulation activity in subtype C Nef clones. Similarly,
88S correlated with increased CD4 downregulation activ-
ity in subtype C in both clinical isolates and site-directed
mutagenesis experiments; however, this residue was least
frequent in this subtype, which may explain in part
the modest reduction in CD4 downregulation activity
observed among subtype C Nef clones.
Some limitations of this study require mention. First,
a minority (15 of 360, 4.2%) of Nef clones with poor
expression and poor function were excluded from analysis
because we could not rule out in vitro defects in protein
expression or stability resulting from PCR or cloning
artifacts. Although our overall results are robust to the
inclusion or exclusion of these clones (not shown), it is
intriguing that a higher proportion of poorly functional
Nef clones were isolated from chronic subtype C-infected
individuals. Follow-up studies to test this directly are
therefore warranted. Second, only two Nef activities (CD4
and HLA-I downregulation) were assessed in this study.
Nef is known to perform multiple in vitro functions, and
it remains uncertain which are the most relevant for
in vivo HIV-1 pathogenesis [1]. In addition, Nef function
may vary depending on the infected cell type [16,57], thus
additional work will be necessary to determine whether
our observations extend to primary cells and cell types
other than CD4+ T-lymphocytes. Finally, the potential
confounding effects of socio-demographic and clinical
differences among HIV-1 infections globally represent
major challenges when investigating inter-subtype differ-
ences in viral function or pathogenesis. Our analysis of
a relatively large number of Nef clones collected from
well-characterized cohorts allowed us to control for
these confounding factors and to identify HIV-1 subtype
as an independent predictor of Nef-mediated HLA-I
downregulation function. Nevertheless, our results merit
independent confirmation from additional cohorts, geo-
graphical regions, and viral subtypes.
Conclusions
In conclusion, we observed that the in vitro CD4 and HLA-I
downregulation activities of patient-derived Nef sequences
differed among HIV-1 M group subtypes. We observed a
hierarchy of Nef function - subtype B > A/D >C – where
inter-subtype differences in CD4 downregulation were rela-
tively modest, while differences in HLA-I downregulation
were substantial. Results raise the intriguing hypothesis that
differences in Nef protein function may contribute to
variation in the pathogenicity of HIV-1 subtypes.
Methods
Study subjects
Nef sequences were derived from 360 antiretroviral naïve
individuals chronically infected with HIV-1 subtypes A(N = 96), B (N = 93), C (N = 85) and D (N= 86) (Table 1).
All 96 subtype A, all 86 subtype D, and two subtype C
sequences were derived from two cohorts in Uganda:
the Adherence Monitoring Uganda (AMU) cohort from
Kampala [58] and the Uganda AIDS Rural Treatment
Outcomes (UARTO) cohort from Mbarara [59]. A total of
92 subtype B sequences were derived from the HAART
Observational Medical Evaluation and Research (HOMER)
Cohort from British Columbia, Canada [46,60]. A total of
83 subtype C sequences and one subtype B sequence were
derived from the Sinikithemba cohort from Durban, South
Africa [61]. Specimens were randomly selected based on
the availability of stored plasma HIV-1 RNA or first-round
plasma RNA-derived PCR products spanning the nef
region ([60] and unpublished data). The study was
approved by all relevant institutional review boards; all
subjects provided written informed consent or specimens
were anonymized according to REB-approved procedures.Amplification of nef
Amplification of plasma HIV-1 nef was performed by
nested RT-PCR using subtype-specific first-round primers
and high-fidelity enzymes. This was followed by second
round PCR using a high-fidelity enzyme (Roche Expand
HiFi™) and novel primers capable of amplifying subtypes
A, B, C, and D that additionally contained AscI (forward)
and SacII (reverse) restriction sites for cloning. The
second round primer sequences were: Forward 5′-AGAG
CACCGGCGCGCCTCCACATACCTASAAGAATMAGAC
ARG-3′ (Asc I site bolded, HXB2 nucleotides 8746-8772
italicized) and Reverse 5′-GCCTCCGCGGATCGATCAGG
CCACRCCTCCCTGGAAASKCCC-3′ (SacII site bolded,
HXB2 nucleotides 9474-9449 italicized). Amplicons were
purified using the QIAQuick PCR purification kit (Qiagen)
prior to cloning.Cloning and sequencing of nef
The pSELECT-GFPzeo expression plasmid (Invivogen),
modified by insertion of a linker containing AscI and
SacII restriction sites, was digested with AscI and SacII,
and purified by electrophoresis and gel extraction (GeneJet
gel extraction kit, Thermo Scientific) to isolate the cut plas-
mid. Each nef PCR product was digested with AscI and
SacII and ligated into the cut pSELECT-GFP plasmid using
5U T4 ligase per μg DNA (6:1 molar ratio of nef insert
to vector). The ligation mixture was transformed into
OneShot TOP10 competent cells (Invitrogen) according
to manufacturer’s instructions, and cells were plated
onto Luria-Bertani (LB) agar plates containing zeocin. A
single colony was propagated overnight in LB broth,
and plasmid DNA purified using a Qiagen miniprep kit.
Restriction enzyme digests and electrophoresis were
used to confirm the presence of the nef gene.
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bi-directionally using the ABI Prism Big Dye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems). Sequence
data were generated with the ABI 3130xl Genetic
Analyzer (Applied Biosystems) and edited in Sequencher
4.8 (GeneCodes). Nef sequences were aligned to HXB2
and insertions with respect to HXB2 stripped out using
HyPhy [62]. For each patient, CD4 and HLA-I down-
regulation was measured for a single nef clone with an
intact open reading frame that was free of gross genetic
defects, such as large deletions, and that was representative
of the original bulk sequence by phylogenetic analysis [63].
HIV-1 subtypes of all nef clones were confirmed using the
recombinant identification program (RIP; http://www.
hiv.lanl.gov/content/sequence/RIP/RIP.html) and sub-
type grouping was corroborated in a maximum likelihood
phylogenetic tree [63]. Nef clonal sequences are available
as Genbank accession numbers KC906733-KC907077.
Subtype B and C consensus sequences (2004 consenses,
available at http://www.hiv.lanl.gov/content/sequence/
NEWALIGN/align.html) were commercially synthesized
(Integrated DNA Technologies) and cloned into pSELECT-
GFP. Site-directed mutagenesis of these templates was
performed using the QuikChange XL system (Stratagene).
CD4 and HLA-I downregulation assays
CD4 and HLA-I downregulation activity for each Nef
clone was measured using a CEM-derived T cell line that
expresses high levels of CD4 and HLA-A*02 (CEM-A*02).
CEM T cells were transduced with a murine stem cell
virus (MSCV) retroviral vector (Clontech) encoding
human HLA-A*0201 and progeny were selected using
puromycin. Surface expression of CD4 and HLA-A*02
was confirmed by flow cytometry, and double-positive cells
were sorted. Cells used in experiments were maintained in
R10 medium lacking puromycin for no longer than 3-4
weeks following puromycin selection. CEM-A*02 cells
(300,000) were transfected by electroporation at 250 V and
950 μF with 4 μg of Nef clone and incubated for 20-24
hours. Separate CMV and human EF1 promoters in the
pSELECT plasmid allow simultaneous expression of GFP
and the nef insert, respectively, in transfected cells. Cells
were stained at 20-24 hours post-transfection with
APC-labeled anti-CD4 and PE-labeled anti-HLA-A*02
antibodies (BD Biosciences) and cell surface expression
was measured in transfected (GFP-positive) cells by flow
cytometry. For patient-derived Nef clones, the median
fluorescence intensity (MFI) of CD4 or HLA-I expression
in GFP-positive cells was normalized to the MFI of CD4
or HLA-I expression for the negative control (empty
pSELECT-GFP plasmid) and positive control (SF2 nef
cloned into the pSELECT-GFP plasmid) to determine the
relative CD4 or HLA-I downregulation capacity: (negative
control – patient Nef)/(negative control – positivecontrol). A normalized MFI value of 0% indicates no
downregulation activity and a value of 100% indicates
downregulation capacity equivalent to that of the positive
control, respectively. For a subset of Nef clones (n = 24,
representing a range of HLA-A*02 downregulation func-
tions), HLA-B downregulation activity was measured using
a CEM cell line stably expressing HLA-B*07 (generated
similarly using MSCV) and a PE-labeled anti-HLA-B*07
antibody (BD Biosciences). All assays were performed in
duplicate and results are presented as the mean of these
measurements.
Western blot analysis
Steady state Nef protein levels were measured by Western
blotting for all Nef clones that displayed poor (<35%)
function for both CD4 and HLA-I downregulation (n = 22
total; 4 subtype A, 2 subtype B, 14 subtype C and 2
subtype D) as well as a random selection of 60 clones
with CD4 and HLA-I downregulation functions above
this threshold. Positive (SF2 Nef ) and negative (empty
pSELECT vector) controls were included in all Western
blot experiments. A total of 1 × 106 CEM cells were
transfected by electroporation with 10 μg of Nef clones.
After 24 hours, cell pellets were collected for preparation
of total cell lysates as described previously [57]. Samples
were subjected to SDS-PAGE and proteins electro-blotted
onto nitrocellulose membrane. HIV-1 Nef was detected
using rabbit polyclonal anti-HIV-1 Nef serum (1:5,000
dilution) (NIH AIDS Research and Reference Reagent
Program, USA) primary antibody, followed by horseradish
peroxidase (HRP)-conjugated donkey anti-rabbit IgG
(1:50,000) (Amersham Biosciences). Nef clones that ex-
hibited poor detection were subsequently probed using
sheep polyclonal anti-HIV-1 Nef serum ARP 444 (1:2,000)
(NIBSC Center for AIDS Reagents, UK) primary antibody,
followed by HRP donkey anti-sheep IgG (1:50,000) (Jackson
ImmunoResearch Europe Ltd). Actin expression was
simultaneously quantified in all experiments. Band in-
tensities were quantified using ImageQuant LAS 4000
(GE Healthcare Life Sciences).
Statistical analysis
Nef CD4 and HLA-I downregulation capacities were
compared between subtypes using Kruskal-Wallis with
Dunn’s multiple comparisons post-hoc tests. Spearman’s or
Pearson’s correlation were used to assess the relationships
between Nef-mediated activities and between Nef CD4/
HLA-I downregulation capacities and Nef sequence length.
Socio-demographic and clinical parameters were com-
pared among subtypes using the Kruskal-Wallis test for
continuous variables and Fisher’s Exact Test for categorical
variables.
The relationship between Nef function and socio-
demographic or clinical factors was assessed by calculating
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investigated were sex (male vs. female [reference group]),
age (per year increment), log10 plasma viral load (per log10
increment), logCD4 count (per log10 increment) and
HIV-1 subtype (reference group subtype B). All variables
p < 0.1 in the univariate analysis were included in the
multivariable model.
In analyses stratified by subtype, the Mann-Whitney U
test was used to identify common amino acid variants
associated with significantly increased or decreased
Nef-mediated CD4/HLA-I downregulation function. A
frequency cut-off (n ≥ 5) was used to exclude rare amino
acid variants. Q-values, the p-value analogue of the false
discovery rate (FDR), were calculated to account for mul-
tiple comparisons [64]. Fisher’s exact test, with Bonferroni
correction for multiple tests, was used to test for signifi-
cance of differences >25% in the frequency of amino acids
between subtype C sequences with high function and
those with the lowest function. Inter-subtype differences in
the frequencies of specific amino acids were investigated
using the Chi-square test [45]. The significance cut-off for
all analyses was p < 0.05, and q ≤ 0.4 where appropriate.
Additional file
Additional file 1: Table S1. Created using Microsoft Excel. Contains
HXB2-aligned, gap-stripped Nef amino acid sequences from all clones
and their associated CD4 and HLA-I downregulation functions.
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